Literature DB >> 32144420

A troublesome burden, the amplification of EGFR in glioblastoma!

Mina Lobbous1, L Burt Nabors1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32144420      PMCID： PMC7229254          DOI： 10.1093/neuonc/noaa055

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN： 1522-8517            Impact factor:   12.300


× No keyword cloud information.
  9 in total

1.  Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma.

Authors:  David A Reardon; Louis B Nabors; Warren P Mason; James R Perry; William Shapiro; Petr Kavan; David Mathieu; Surasak Phuphanich; Agnieszka Cseh; Yali Fu; Julie Cong; Sven Wind; David D Eisenstat
Journal:  Neuro Oncol       Date:  2014-08-19       Impact factor: 12.300

2.  Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial.

Authors:  Michael Weller; Nicholas Butowski; David D Tran; Lawrence D Recht; Michael Lim; Hal Hirte; Lynn Ashby; Laszlo Mechtler; Samuel A Goldlust; Fabio Iwamoto; Jan Drappatz; Donald M O'Rourke; Mark Wong; Mark G Hamilton; Gaetano Finocchiaro; James Perry; Wolfgang Wick; Jennifer Green; Yi He; Christopher D Turner; Michael J Yellin; Tibor Keler; Thomas A Davis; Roger Stupp; John H Sampson
Journal:  Lancet Oncol       Date:  2017-08-23       Impact factor: 41.316

3.  Rindopepimut with Bevacizumab for Patients with Relapsed EGFRvIII-Expressing Glioblastoma (ReACT): Results of a Double-Blind Randomized Phase II Trial.

Authors:  David A Reardon; Annick Desjardins; James J Vredenburgh; Donald M O'Rourke; David D Tran; Karen L Fink; Louis B Nabors; Gordon Li; Daniela A Bota; Rimas V Lukas; Lynn S Ashby; J Paul Duic; Maciej M Mrugala; Scott Cruickshank; Laura Vitale; Yi He; Jennifer A Green; Michael J Yellin; Christopher D Turner; Tibor Keler; Thomas A Davis; John H Sampson
Journal:  Clin Cancer Res       Date:  2020-02-07       Impact factor: 12.531

4.  Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.

Authors:  Ingo K Mellinghoff; Maria Y Wang; Igor Vivanco; Daphne A Haas-Kogan; Shaojun Zhu; Ederlyn Q Dia; Kan V Lu; Koji Yoshimoto; Julie H Y Huang; Dennis J Chute; Bridget L Riggs; Steve Horvath; Linda M Liau; Webster K Cavenee; P Nagesh Rao; Rameen Beroukhim; Timothy C Peck; Jeffrey C Lee; William R Sellers; David Stokoe; Michael Prados; Timothy F Cloughesy; Charles L Sawyers; Paul S Mischel
Journal:  N Engl J Med       Date:  2005-11-10       Impact factor: 91.245

5.  Changes in the EGFR amplification and EGFRvIII expression between paired primary and recurrent glioblastomas.

Authors:  Martin J van den Bent; Ya Gao; Melissa Kerkhof; Johan M Kros; Thierry Gorlia; Kitty van Zwieten; Jory Prince; Sjoerd van Duinen; Peter A Sillevis Smitt; Martin Taphoorn; Pim J French
Journal:  Neuro Oncol       Date:  2015-02-16       Impact factor: 12.300

6.  The role of base excision repair in the sensitivity and resistance to temozolomide-mediated cell death.

Authors:  Ram N Trivedi; Karen H Almeida; Jamie L Fornsaglio; Sandra Schamus; Robert W Sobol
Journal:  Cancer Res       Date:  2005-07-15       Impact factor: 12.701

Review 7.  Glioblastoma targeted therapy: updated approaches from recent biological insights.

Authors:  M Touat; A Idbaih; M Sanson; K L Ligon
Journal:  Ann Oncol       Date:  2017-07-01       Impact factor: 32.976

8.  Efficacy and safety results of ABT-414 in combination with radiation and temozolomide in newly diagnosed glioblastoma.

Authors:  David A Reardon; Andrew B Lassman; Martin van den Bent; Priya Kumthekar; Ryan Merrell; Andrew M Scott; Lisa Fichtel; Erik P Sulman; Erica Gomez; JuDee Fischer; Ho-Jin Lee; Wijith Munasinghe; Hao Xiong; Helen Mandich; Lisa Roberts-Rapp; Peter Ansell; Kyle D Holen; Hui K Gan
Journal:  Neuro Oncol       Date:  2017-07-01       Impact factor: 12.300

9.  INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma.

Authors:  Martin Van Den Bent; Marica Eoli; Juan Manuel Sepulveda; Marion Smits; Annemiek Walenkamp; Jean-Sebastian Frenel; Enrico Franceschi; Paul M Clement; Olivier Chinot; Filip De Vos; Nicolas Whenham; Paul Sanghera; Michael Weller; H J Dubbink; Pim French; Jim Looman; Jyotirmoy Dey; Scott Krause; Pete Ansell; Sarah Nuyens; Maarten Spruyt; Joana Brilhante; Corneel Coens; Thierry Gorlia; Vassilis Golfinopoulos
Journal:  Neuro Oncol       Date:  2020-05-15       Impact factor: 12.300
  9 in total
  1 in total

Review 1.  Mechanisms of EGFR Resistance in Glioblastoma.

Authors:  Peter C Pan; Rajiv S Magge
Journal:  Int J Mol Sci       Date:  2020-11-11       Impact factor: 5.923
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.